Pharmaceuticals and Healthcare - Research and Markets - RSS Feed

Pharmaceutical IT Spending Forecast in the UK to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:58 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in the UK. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in the UK through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in the UK in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in the UK accounting for 54.7% of the total IT spending in 2007.

Pharmaceutical IT spending in the UK is expected to increase at a compound annual growth rate (CAGR) of 4.9% over the 2008-13 period.

The UK accounted for 10.5% of the total pharmaceutical IT spending in Europe in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in the UK

Pharmaceutical IT Spending Forecast in Canada to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:58 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Canada. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Canada through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Canada in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Canada accounting for 55.1% of the total IT spending in 2007.

Pharmaceutical IT spending in Canada is expected to increase at a compound annual growth rate (CAGR) of 4.7% over the 2008-13 period.

Canada accounted for 3.5% of the total pharmaceutical IT spending in North America in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Canada

Pharmaceutical IT Spending Forecast in the US to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:58 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in the US. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in the US through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in the United States in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in the US accounting for 56% of the total IT spending in 2007.

Pharmaceutical IT spending in the US is expected to increase at a compound annual growth rate (CAGR) of 5.5% over the 2008-13 period.

The US accounted for 96.5% of the total pharmaceutical IT spending in North America in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in the US

Pharmaceutical IT Spending Forecast in Mexico to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:58 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Mexico. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Mexico through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Mexico in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Mexico accounting for 57.8% of the total IT spending in 2007.

Pharmaceutical IT spending in Mexico is expected to increase at a compound annual growth rate (CAGR) of 5.7% over the 2008-13 period.

Mexico accounted for 33.5% of the total pharmaceutical IT spending in South Central America in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Mexico

Pharmaceutical IT Spending in Spain to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:57 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Spain. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Spain through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Spain in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Spain accounting for 56.4% of the total IT spending in 2007.

Pharmaceutical IT spending in Spain is expected to increase at a compound annual growth rate (CAGR) of 4.1% over the 2008-13 period.

Spain accounted for 6.8% of the total pharmaceutical IT spending in Europe in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Spain

Pharmaceutical IT Spending in France to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:57 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in France. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in France through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in France in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in France accounting for 55.8% of the total IT spending in 2007.

Pharmaceutical IT spending in France is expected to increase at a compound annual growth rate (CAGR) of 6.6% over the 2008-13 period.

France accounted for 19.2% of the total pharmaceutical IT spending in Europe in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in France

Pharmaceutical IT Spending in South Korea to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:57 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in South Korea. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in South Korea through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in South Korea in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in South Korea accounting for 56.6% of the total IT spending in 2007.

Pharmaceutical IT spending in South Korea is expected to increase at a compound annual growth rate (CAGR) of 4.6% over the 2008-13 period.

South Korea accounted for 6.2% of the total pharmaceutical IT spending in Asia Pacific in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in South Korea

Pharmaceutical IT Spending in India to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:57 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in India. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in India through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in India in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in India accounting for 55.8% of the total IT spending in 2007.

Pharmaceutical IT spending in India is expected to increase at a compound annual growth rate (CAGR) of 13.8% over the 2008-13 period.

India accounted for 5% of the total pharmaceutical IT spending in Asia Pacific in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in India

Pharmaceutical IT Spending in Japan to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:56 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Japan. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Japan through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Japan in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Japan accounting for 57.7% of the total IT spending in 2007.

Pharmaceutical IT spending in Japan is expected to increase at a compound annual growth rate (CAGR) of 5% over the 2008-13 period.

Japan accounted for 64.6% of the total pharmaceutical IT spending in Asia Pacific in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Japan

Pharmaceutical IT Spending in Italy to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:56 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Italy. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Italy through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Italy in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Italy accounting for 54.8% of the total IT spending in 2007.

Pharmaceutical IT spending in Italy is expected to increase at a compound annual growth rate (CAGR) of 4.2% over the 2008-13 period.

Italy accounted for 10.3% of the total pharmaceutical IT spending in Europe in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Italy

Pharmaceutical IT Spending in Germany to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:56 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Germany. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Germany through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Germany in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Germany accounting for 56.1% of the total IT spending in 2007.

Pharmaceutical IT spending in Germany is expected to increase at a compound annual growth rate (CAGR) of 5% over the 2008-13 period.

Germany accounted for 18.4% of the total pharmaceutical IT spending in Europe in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Germany

Pharmaceutical IT Spending in China to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:56 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in China. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in China through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in China in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in China accounting for 56.8% of the total IT spending in 2007.

Pharmaceutical IT spending in China is expected to increase at a compound annual growth rate (CAGR) of 12.1% over the 2008-13 period.

China accounted for 10.7% of the total pharmaceutical IT spending in Asia Pacific in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in China

Pharmaceutical IT Spending in Brazil to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:55 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Brazil. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Brazil through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Brazil in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Brazil accounting for 59.6% of the total IT spending in 2007.

Pharmaceutical IT spending in Brazil is expected to increase at a compound annual growth rate (CAGR) of 4.9% over the 2008-13 period.

Brazil accounted for 26.7% of the total pharmaceutical IT spending in South and Central America in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Brazil

Pharmaceutical IT Spending in Australia to 2013

press@researchandmarkets.com — Wed, 09 Dec 2009 14:52:55 GMT

This databook provides a forecast and analysis of IT spending in the pharma/biotech industries through to 2013 in Australia. The sectors covered include big pharma, mid pharma, biotech, and small pharma/biotech.

Scope

- The databook provides forecasts relating to total pharmaceutical IT spending in Australia through to 2013

- In each sub-sector, pharmaceutical IT spending is segmented by hardware, software and services

- Contains pharmaceutical IT spending forecasts in Australia in relation to the wider region

Highlights of this title

The big pharma sector led the pharmaceutical IT spending in Australia accounting for 56.2% of the total IT spending in 2007.

Pharmaceutical IT spending in Australia is expected to increase at a compound annual growth rate (CAGR) of 6.5% over the 2008-13 period.

Australia accounted for 5.1% of the total pharmaceutical IT spending in Asia Pacific in 2007.

Key reasons to purchase this title

- Understand the opportunity for technology spending in the life science market

- Identify potential areas for spending growth amongst pharmaceutical and biotechnology companies

- Contains an analysis of pharmaceutical IT spending forecast by each sector in Australia

Commercial Insight: Cytotoxic Therapies - Market growth will slow due to increasing genericization

press@researchandmarkets.com — Thu, 23 Jul 2009 08:47:40 GMT

The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs success, generic entry will ensure continued growth. Coupled with the launch of several new brands, steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.

Scope

- In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU and Japan, plus a rest of world snapshot

- Cytotoxic therapy sales forecasts for brands and generics from 2008 to 2018

- Assessment of the leading cancer brands and drug classes to identify key success factors within this sector

- Assess the strategies of several leading players in the cytotoxics market

Highlights of this title

The cytotoxics market was worth $13.8 billion in 2008 across the seven major pharmaceutical markets, and is forecast to grow to $18.7 billion by 2018, achieving a CAGR of 3.1%. The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will contribute significantly to this growth.

In 2008, Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) were the top three cytotoxics, with sales over $1 billion. Despite facing patent expiry during the forecast period and guaranteed generic entry, Taxotere and Eloxatin will remain in the top three in 2018, along with Dacogen.

The key events to impact the cytotoxics market during the forecast period are the launch of new drugs, expansion into new indications and patent expiries. Several blockbuster products with annual sales of over $1 billion are due to undergo patent expiry during the forecast period, however, generic entry will ensure continued market growth.

Key reasons to purchase this title

- Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven m

Forecast Insight: Inflammatory Bowel Disease - New product launches sustain long-term market growth

press@researchandmarkets.com — Thu, 23 Jul 2009 08:47:39 GMT

The inflammatory bowel disease market is set to grow from $2.9 billion in 2008 to $4.5 billion in 2018 across the seven major markets. While The updated forecast will parallel its previous forecast up to 2012, several new product launches, regional expansion and upgraded brand forecast will help to sustain growth in the second half of the forecast period.

Scope

- Analysis of the current and future market dynamics in inflammatory bowel disease across the US, France, Germany, Italy, Spain the UK and Japan

- Assessment of over 25 key marketed inflammatory bowel disease brands and late stage pipeline products

- Snapshot of inflammatory bowel disease drug sales outside the seven major markets

- Insight through key opinion leader comments to support conclusions

Highlights of this title

Several events, such as new product launches and regional expansion, will ensure sustained sales growth in the latter part of the forecast period, overcoming biosimilar entry. The updated forecast shows sales in the seven major markets will reach $4.5 billion in 2018.

SONIC trial data shows a u-turn in previous opinion on beginning anti-TNF in combination with immunosuppressant therapy in biologic- or immunosuppressant-naïve Crohns disease patients. Datamonitor expects any impact from SONIC on clinical practice to emerge slowly within the next 2 years, and will impact across the TNF class.

Cimzia (certolizumab) is better able to compete with Abbotts Humira (adalimumab) in Crohns disease with its new pre-filled syringe formulation. Cimzias monthly dosing schedule together with its pre-filled syringe and lower cost will enable the drug to capture almost a quarter of the US anti-TNF market, in terms of sales, in 2018.

Key reasons to purchase this title

- Understand how new brands Lialda and Apriso will fare against established market players, such as Asacol and Pentasa

- Assess the impact of the launch of Cimzias recent pre-filled syringe and gauge future dynamics within the ant

Pharmaceutical Companies Report - Global Top 10 Pharmaceutical Companies

press@researchandmarkets.com — Thu, 23 Jul 2009 08:47:38 GMT

Scope:

‘Top 10 Global Pharmaceutical Companies Report: Strategic evaluation of industry and key players’ is a business report that provides a comprehensive view of the pharmaceutical industry and its top 10 companies.

The report includes the following:

- Industry analysis including market value, market volume, market share and forecast growth till 2013
- Assessment of intensity of competition based on five-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
- SWOT and 5-year financial analysis of top 10 players in the industry
- Descriptive profiles of the leading players including the strategic initiatives undertaken in the last 12 months

The top 10 companies have been ascertained based on their global revenues for the year ended December 2008.

Highlights:

The global pharmaceuticals industry generated total revenues of $615.1 billion in 2008, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2004-08. The industrys total revenues are expected to touch $734 billion by the end of 2013, representing a CAGR of 3.6% for the 2008-13 period.

The top 10 global pharmaceutical companies recorded revenues of $348.3 billion during 2008, an increase of 4% over 2007. The operating profit of these companies was $81.6 billion during 2008, an increase of 11.6% over 2007. The net profit was $65.1 billion in 2008, an increase of 12.1% over 2007.

The average operating margin of the top 10 companies was 23.3% in 2008 as compared to 23.1% in 2007. The net margin was 20.2% in 2008 as compared with 19.3% in 2007.

Since 2004, the global pharmaceuticals market has witnessed moderate growth across different geographies. The market growth is expected to decelerate through to 2013 due to increased number of patent expiries and intensifying competition from generics.

Reasons to Purchase

- Gain insights into the industry, leading companies and competitors through a single report
- Benchmark the leading pl

Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition

press@researchandmarkets.com — Thu, 23 Jul 2009 08:47:38 GMT

Driven primarily by continued uptake of Shires market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shires Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.

Scope

- This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.

- Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.

- Provides a global market snapshot by including sales analysis for leading ADHD brands outside the seven major markets.

- Key conclusions are supported by key opinion leader comment.

Highlights of this title

The April 2009 launch of generic competition in the US will cause sales of Shires leading ADHD product, Adderall XR, to decline sharply. However, Datamonitor maintains the expectation that Shire will remain the dominant player in the ADHD market over the forecast period due to the companys broad portfolio of products.

Intuniv (guanfacine hydrochloride) represents Shires first venture into the non-stimulant segment of the ADHD market. Datamonitor believes Shire will market Intuniv as a second-line treatment option, due to clinical data demonstrating inferior efficacy to stimulant treatments, putting it in direct competition with Strattera.

The publication of a US government-sponsored study reporting an association between ADHD treatments and sudden unexplained death among pediatrics will reignite the debate over the safety of ADHD drugs in children. The media coverage will cause some parents in the US to choose to discontinue or not begin stimulant therapy for their children.

Key reasons to purchase this title

- Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast pe

Inflammatory Bowel Disease Market Forecast

press@researchandmarkets.com — Thu, 23 Jul 2009 08:47:37 GMT

This model provides detailed sales and volume forecast data for the inflammatory bowel disease market. Including Crohn's disease and ulcerative colitis market sizing, within the context of total brand sales across the seven major markets.

Key reasons to purchase this title

- Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world

- Understand IBD market trends and assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products

- Access a case study assessing the likelihood of ulcerative colitis approval for Humira and Simponi with three alternative scenario forecasts

Attention-Deficit Hyperactivity Disorder Market Forecast

press@researchandmarkets.com — Thu, 23 Jul 2009 08:47:37 GMT

IP VPN and Network Convergence Adoption—US Healthcare

press@researchandmarkets.com — Thu, 08 Nov 2007 17:18:05 GMT

IP VPN technology has an established base within US healthcare and represents an important segment of today’s data services. Based on In-Stat's 2007 IP Communications and Convergence survey of 1,000 US IT professionals, which included 119 respondents in the healthcare sector, this paper provides valuable insight into:-Current and near-term overall IP VPN deployment.
-Current and near-term IP VPN deployment by type.
-Most important factors considered by healthcare IT professionals when selecting an IP VPN.
-Current and near-term adoption trends for convergence of voice, video, and data.
-Most important factors driving convergence in the healthcare sector.
-Current and near-term trends for use of QoS/CoS.

Mobility Investment In Healthcare H2 2006 (Databook)

press@researchandmarkets.com — Thu, 11 Oct 2007 13:19:52 GMT

Introduction

This databook from the Technology Trends service helps vendors to understand current and forthcoming investment in mobility solutions in manufacturing. The data has been drawn from interviews with 40 IT managers conducted in H2 2006.

Scope

Our has interviewed 400 IT decision makers about their investment in 8 core enterprise technologies. Interviews have been conducted with IT decision makers to gain an understanding of their attitudes to, and adoption of, various technologies. The interviews have been spread evenly across 8 geographical markets and span 10 vertical markets and 5 enterprise size bands.

Highlights

Over the course of 2006, we are publishing over 500 databooks with Technology Trends data cut by technology, vertical market, geography and size band.

Reasons to Purchase

Gain insight into key technology investment patterns and trends in target markets. Understand evolving customer IT budgets, attitudes to technology adoption, technology decision-making processes, and perception of technology vendors. Enable your sales, marketing and product teams to address your IT audience.

Content Management Investment In Healthcare H2 2006 (Databook)

press@researchandmarkets.com — Thu, 11 Oct 2007 11:55:26 GMT

Introduction

This databook from the Technology Trends service helps vendors to understand the current and forthcoming investment in content management solutions in healthcare. The data has been drawn from interviews with 40 IT managers conducted in H2 2006.

Scope

Our has interviewed 400 IT decision makers about their investment in 8 core enterprise technologies. Interviews have been conducted with IT decision makers to gain an understanding of their attitudes to, and adoption of, various technologies. The interviews have been spread evenly across 8 geographical markets and span 10 vertical markets and 5 enterprise size bands.

Highlights

Over the course of 2006, we are publishing over 500 databooks with Technology Trends data cut by technology, vertical market, geography and size band.

Reasons to Purchase

Gain insight into key technology investment patterns and trends in target markets. Understand evolving customer IT budgets, attitudes to technology adoption, technology decision-making processes, and perception of technology vendors. Enable your sales, marketing and product teams to address your IT audience.

Voice/Data Convergence Investment In Healthcare H2 2006 (Databook)

press@researchandmarkets.com — Thu, 11 Oct 2007 11:55:25 GMT

Introduction

This databook from the Technology Trends service helps vendors to understand the current and forthcoming investment in voice/data convergence solutions in healthcare. The data has been drawn from interviews with 40 IT managers conducted in H2 2006.

Scope

Our has interviewed 400 IT decision makers about their investment in 8 core enterprise technologies. Interviews have been conducted with IT decision makers to gain an understanding of their attitudes to, and adoption of, various technologies. The interviews have been spread evenly across 8 geographical markets and span 10 vertical markets and 5 enterprise size bands.

Highlights

Over the course of 2006, we are publishing over 500 databooks with Technology Trends data cut by technology, vertical market, geography and size band.

Reasons to Purchase

Gain insight into key technology investment patterns and trends in target markets. Understand evolving customer IT budgets, attitudes to technology adoption, technology decision-making processes, and perception of technology vendors. Enable your sales, marketing and product teams to address your IT audience.

Enterprise Applications Investment In Healthcare H2 2006 (Databook)

press@researchandmarkets.com — Thu, 11 Oct 2007 11:55:22 GMT

Introduction

This databook from the Technology Trends service helps vendors to understand the current and forthcoming investment in enterprise applications in healthcare. The data has been drawn from interviews with 40 IT managers conducted in H2 2006.

Scope

Our has interviewed 400 IT decision makers about their investment in 8 core enterprise technologies. Interviews have been conducted with IT decision makers to gain an understanding of their attitudes to, and adoption of, various technologies. The interviews have been spread evenly across 8 geographical markets and span 10 vertical markets and 5 enterprise size bands.

Highlights

Over the course of 2006, we are publishing over 500 databooks with Technology Trends data cut by technology, vertical market, geography and size band.

Reasons to Purchase

Gain insight into key technology investment patterns and trends in target markets. Understand evolving customer IT budgets, attitudes to technology adoption, technology decision-making processes, and perception of technology vendors. Enable your sales, marketing and product teams to address your IT audience.

US Healthcare Market: Managed Services Adoption Trends and Spending

press@researchandmarkets.com — Fri, 21 Sep 2007 11:39:44 GMT

We predict steadily increasing managed services spending growth in the healthcare market with a 9% CAGR through 2011-slightly higher than average managed services spending percentage growth in the overall US business market.
This report covers managed services adoption trends in the US healthcare market. There are three main sections of this report.

The first section focuses on demand for managed services, including managed services adoption trends for multiple business network functions. Also covered is demand for fully-managed IP telephony and fully-managed desktop solutions.

The second section focuses on adoption of utility computing, or "on-demand" services in the healthcare market. Covered is demand for on-demand network/bandwidth capacity, computer storage capacity, and server/CPU capacity.

The third section focuses on managed services spending. Survey data tables that detail current and future demand for all surveyed business network functions are broken down comparing the healthcare market to the total US business market.

The report is based upon primary research obtained in a recent survey that included 199 US healthcare market business-network decision makers.

Commercial & Pipeline Insight: Hospital Antibacterials A market beyond MRSA

press@researchandmarkets.com — Wed, 12 Sep 2007 12:11:48 GMT

Introduction

The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.

Scope

n-depth analysis of the hospital market sector across Japan, US, France, Italy, Germany Spain and the UK Product by product analysis of the key marketed and pipeline brands that will determine the markets evolution An assessment of key unmet needs and the opportunities they offer for new product development Case study analysis of the commercial implications of antibiotic drug development and commercialization

Highlights

The total value of the hospital antibacterial market is $9.9bn, but generic incursion has caused this to slump over the 2003-2006 period. Within this market, a core group of products, accounting for $5.7 billion have managed to maintain a modest growth of 3%. As sequential market leaders face patent expiry, competition within the generic industry will increase on oral formulations, leading select generic manufacturers to target the IV market with premium generic products. High numbers of Gram-positive targeted products imply very distinct winners and losers. Astellas Arbelic Cubicin and Zeven have strong commercial backing, but oritavancin, ceftaroline and subsequent entrants will find that generic incursion combined with the marketing might of strong entrants form a formidable barrier to the success.

Reasons to Purchase

Balance the clinical and commercial aspects of key marketed and pipeline products to understand the future shape of the hospital antibacterials sector Understand the key supplemental clinical analysis that can make a critical difference to drug uptake post-approval Review the changes in class sales that signal the shif

Pipeline Insight: Heart failure Weak pipeline dominated by new indications and add-on diuretics

press@researchandmarkets.com — Mon, 03 Sep 2007 13:42:55 GMT

Introduction

Our expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.

Scope

Comprehensive analysis of the current acute and chronic heart failure pipeline detailing the broad of developmental classes. A detailed clinical and commercial assessment of all key emerging therapies. Epidemiological based sales forecasts for key late-stage developmental heart failure agents in the seven major markets to 2016.

Highlights

The heart failure market is relatively stable, with few drugs being launched in the past five years and many of those launched having significant safety or commercial viability issues. It is also a market with high unmet need waiting to be addressed. Patients with heart failure have a poor prognosis with half of all patients diagnosed with severe heart failure dying within four years. The R&D pipeline for heart failure is a Phase II-heavy, diverse range of novel agents, with 50% all of candidates being in Phase II trials.

Reasons to Purchase

Quantify the future drugs in the acute and chronic heart failure market. Identify licensing opportunities based on company portfolio and market needs. Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs.

Launch Strategies - Analyzing Market Trends and Regulatory Impacts

press@researchandmarkets.com — Mon, 03 Sep 2007 13:42:52 GMT

Introduction

With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.

Scope

Analysis of brand drug launch strategies in the US and five major European markets Examination of pit falls manufacturers face following approval, which can frequently delay the launch of a product Identification of commercialization strategies employed by manufacturers to increase the market voice of their product prior to and post launch Provides case-studies of both the most successful drug launches as well as launch failures during 200206

Highlights

Although the number of NDAs submitted to the FDA continue to rise year on year, the number of new molecular entities is on the decline, reflecting the increased cost of developing novel products With a decrease in R&D productivity in recent years, in order to maximize the return on investment, drugs launched in the US and 5EU markets between 2002 and 2006, have typically been commercialized by a single pharmaceutical company By 2012, average sales per drug per year are predicted to be lower, and manufacturers will have a greater reliance on launch portfolio compensating for revenues loses of marketed products, due to patent expiries

Reasons to Purchase

Gain insight into launch strategies employed by pharmaceutical manufacturers today Understand successful launch strategies and identify how these can best be implemented Benchmark the success of product launches in order to improve future launch planning and forecasting

Business Blogging for Pharma

press@researchandmarkets.com — Mon, 03 Sep 2007 13:42:49 GMT

Introduction

Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries.

Scope

Introduction to social media and their relevance to the pharmaceutical industry Sizes and assesses the growth in the blogosphere in the US, Europe and Asia Looks at blogging in other industries and highlights lessons that pharmaceutical companies can learn Discusses current examples of pharmaceutical blogging and considers the future of blogging in the pharmaceutical industry

Highlights

Strategic use of Internet applications, including online communities and blogs, will allow pharmaceutical companies to increase their awareness of the needs and concerns of their patient and caregiver audiences. As blogs and online forums are so frequently updated they can be a good indication of the current market. Companies from a broad range of industries have had success in authoring blogs and hosting online forums for their consumers. Some of the benefits these companies have enjoyed include direct communication with influential consumers, higher search engine rankings for key search terms and the ability to respond quickly to marketplace events. Much of the delay in pharmaceutical companies entering the public blogosphere can be attributed to concerns about the liabilities associated with blogging. Many embattled companies, which were already dealing with high profile withdrawals and associated lawsuits, have not felt the need to expose themselves further to public criticism.

Reasons to Purchase

Identify the best and worst practice lessons that can be learned from examples of business blogging in other industries. Understand the potential liabilities of busine

U.S. Revenues for Knee Implants, 2005-2010

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:24 GMT

This TriMark Publications Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specific data points. The Database Table is NOT a report or a comprehensive analysis.

U.S. Revenues for Hip Implants, 2005-2010

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:24 GMT

U.S. Knee Implant Market by Volume, 2002 and 2008

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:24 GMT

Hip and Knee Replacement Market

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:23 GMT

Global Sales of Animal Health Antibiotics, 2004-2009

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:22 GMT

European Revenues for Knee Implants, 2005-2010

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:22 GMT

European Revenues for Hip Implants, 2005-2010

press@researchandmarkets.com — Tue, 28 Aug 2007 14:15:21 GMT

R&D Strategies: Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity

press@researchandmarkets.com — Fri, 17 Aug 2007 11:36:19 GMT

Introduction

Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity

Scope

Overview of the pressures facing drug developers, including an analysis of whether the industry is facing an R&D productivity crisis In-depth analysis of R&D deal activity, together with a pipeline snapshot, to identify trends that are shaping the R&D environment Identification of strategy optimization recommendations designed to drive up R&D productivity Evaluation of case-studies of Big Pharma R&D strategies to determine how these companies are addressing the productivity problem

Highlights

Over the last decade, significant investment in novel technologies has failed to yield a substantial increase in innovative drugs To drive up future productivity, drug developers are making either incremental changes to fine-tune the R&D process or they are implementing paradigm changes to radically alter the way that R&D is carried out R&D productivity depends on accelerating and boosting the output of drug discovery and development, and there are a range of strategies to do this, including optimizing the R&D model and improving the R&D process

Reasons to Purchase

Gain a clear understanding of the factors driving drug developers to change R&D strategies Gain insight into the trends in R&D clinical pipeline deal activity and pipeline focus Understand how a wide of strategies can optimize R&D productivity and identify how these can best be implemented

Patient Empowerment: empowered patients can change healthcare outcomes and impact the pharmaceutical industry

press@researchandmarkets.com — Fri, 10 Aug 2007 14:17:39 GMT

Introduction

Our has identified the key trends and events that drive patient empowerment and impact the pharmaceutical industry. These range from the increased access to information via internet and the rising pressures of cost containment through to how patient empowerment is affecting access to drugs as well as changing pharmaceutical marketing strategies and their public image.

Scope

Overview of the key trends driving patient empowerment Overview of how empowered patients and patient advocacy groups can change healthcare outcomes including case studies Analysis of the marketing strategies that companies are using to address the rise in patient education and harness patient power Identification of future trends shaping evolution of patient empowerment

Highlights

Increased access to the internet, the rising pressures of cost containment and the changing patient-physician relationship are the key factors driving the rise in patient empowerment. Disease characteristics are one of the key factors determining how powerful different patient groups are. Empowered patients can influence most healthcare outcomes: access to drugs, reimbursement policies, approval of new drugs, clinical trial recruitment, patient compliance and prescription rates. However they can also lead to reduction in drug prices and negative publicity for the pharmaceutical industry. Pharmaceutical companies are investing effort into harnessing patient power through working with patient advocacy groups. Legal restrictions and increased public scrutiny are limiting how companies can work with patient groups and communication of medical information is the main form of contact in Europe.

Reasons to Purchase

Identify the key trends that are driving a rise in patient empowerment Understand how patient advocacy groups can affect the pharmaceutical industry Gain insight into how pharmaceutical companies are working with patient advocacy groups and how marketing strategies are becoming more patient-focu

Pipeline and Commercial Insight: Pediatric and Adolescent Vaccines

press@researchandmarkets.com — Fri, 10 Aug 2007 14:17:37 GMT

Introduction

The pediatric and adolescent vaccines market encompasses many different classes. DTP and MMR combinations continue to form the mainstay of childhood immunization; however, their growth potential is limited. The key opportunities lie in novel, innovative additions to established schedules, particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and HPV (Gardasil) vaccines.

Scope

Strategic analysis of the pediatric and adolescent vaccines market across the seven major markets and of key companies in the sector Thorough assessment of underlying commercial and clinical influencers shaping the pediatric and adolescent vaccines market Patient-based forecasts for key vaccine classes and products according to recommended vaccination groups and coverage rates in the seven major markets In-depth discussion of novel vaccine pipeline candidates and discussion of their future potential

Highlights

Driven by the launch of novel, high-price vaccines such as Gardasil or RotaTeq, the pediatric and adolescent vaccines market is experiencing a rapid growth. Wyeths Prevnar has emerged as the first blockbuster vaccine, demonstrating that innovative vaccines can command high prices and yield high revenues in the pediatric vaccines market. The main future opportunities lie in the pneumococcal, meningococcal and HPV vaccine sectors, where there is a large medical need. Particularly a vaccine against infections with N. meningitidis B would have a potentially huge commercial. Key challenges include the reluctance of healthcare providers to pay for increasingly expensive vaccines and the lack of widespread organized vaccination programs for school children and teenagers. With an increasing focus on adolescent vaccines such as Gardasil or Menactra, better ways to reach adolescents for vaccination will have to be found.

Reasons to Purchase

Review clinical and commercial factors driving new product decisions and the strategies of key players in the pediatric a

Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries

press@researchandmarkets.com — Fri, 20 Jul 2007 10:23:39 GMT

Introduction

Our expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartiss Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizers Norvasc and Mercks Cozaar, will restrain market growth.

Scope

Event-driven sales forecasts for 2007-16 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan. Country and market specific issues that will impact sales opportunities and market landscape, including key patent expiries and product launches. Case studies assessing the blockbuster potential of Novartiss direct renin inhibitor, Tekturna, and the impact of ESC/ESH guideline reform in Europe. Comprehensive analysis of the current antihypertensives pipeline, including a clinical and commercial assessment of all key emerging therapies.

Highlights

The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies. Cozaars patent expiry in the US, has the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market. Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve international blockbuster status and Exforge will achieve sales of at least $800m, set back slightly by the premature expiry of Pfizers Norvasc patent.

Reasons to Purchase

Quantify the future size of the antihypertensives market and identify opportunities for new products. Learn how recent European healthcar

Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential

press@researchandmarkets.com — Fri, 20 Jul 2007 10:23:39 GMT

Introduction

Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.

Scope

Indication based forecasts for asthma/COPD products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance

Highlights

Asthma/COPD sales in the seven major markets are expected to grow to over $24 billion annually by 2010 and drop slightly thereafter due to patent expiries of key products. The ICS/LABA class is set to remain the leading class by value throughout, while the LAMA market will experience the strongest growth, particularly in COPD. A once-daily LABA/LAMA product should become the top-selling single brand in the seven major markets in 2016, depending on which company launches such a combination product first. However, combined sales of the Advair franchise (Advair/Seretide and once-daily Beyond Advair) will dominate the asthma/COPD market over the next ten years. The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2-agonists (SABAs), increasing this class size significantly. The main beneficiary is expected to be IVAXs (now Teva) ProAir due to its favourable price compared with other marketed HFA SABAs.

Reasons to Purchase

Identify key opportunities and threats that will impact the use and uptake of new and existing products Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds Understand and capitalize on clinical unmet needs in the marke

Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges

press@researchandmarkets.com — Fri, 20 Jul 2007 10:23:38 GMT

Introduction

The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.

Scope

Assessment of each of the seven major markets, key drivers for growth and resistors to growth Overview of the main opportunities and threats in each of the seven major markets Forecast analysis including the key events, among them new product launches, major clinical trials and patent expiries. Overview of two case studies (on CETP inhibitors and on the second wave of patent expiries) including worst and best case scenarios.

Highlights

Despite over 300m people being eligible for treatment in seven major markets, as well as the recommended treatment goals capturing more patients and promoting more aggressive therapy, there is a lot of under-diagnosis and under-treatment. Cost-saving policies further limit the patient potential for branded agents. Lowering of LDL-C treatment goals cannot counteract the impact of cost-saving policies, and does not guarantee a revenue stream for branded agents. This is why there are currently several outcome trials that regard the potential of branded agents (Crestor, Vytorin) in new indications/patient groups, e.g. heart failure and renal disease. Branded statins market share is diminishing. Due to the patent expiries of statins that have taken place in the past five years (especially that of Zocor) and those going to take place in the near future (especially that of Lipitor) the branded statins are losing their market share rapidly.

Reasons to Purchase

Understand key drivers and predict the future performance of key compounds Optimize sales and marketing strategy to counter market threats Develop commercial strategies across the seven major markets

Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit

press@researchandmarkets.com — Fri, 20 Jul 2007 10:23:37 GMT

Introduction

Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI) conditions, which can be referred to collectively as upper GI disorders. Gastric acid suppression remains the cornerstone of therapy in upper GI disorders, with particular focus on reducing symptoms and eradicating H. pylori, if present.

Scope

Analysis of patient potential, unmet needs and clinical trials in upper GI disorders. Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline. Detailed profiles of key compounds in development for use in upper GI disorders, with forecasts of drug revenues to 2016. Discussion of R&D company strategies used in upper GI disorder market, focusing on AstraZeneca and TAP Pharmaceuticals.

Highlights

The upper GI disorder pipeline is small, with only 33 products, and only 3 drugs in Phase III. In a market that is dominated by PPIs, which are becoming increasingly genericized, and with over-the-counter medicines available, pharmaceutical companies appear to be less than willing to enter this competitive market. A key company R&D strategy is the development of specific enantiomers of PPIs. This extends patent life and can result superiority to the racemate mixture. TAP Pharmaceuticals has for dexlansoprazole, and Sidem Pharma and Steba Laboratories are co-developing S-tenatoprazole for GERD. Both are expected to quickly achieve blockbuster status. The inclusion of Nexium (esomeprazole) as a comparator in clinical trials is essential to ensure market success for pipeline products. Companies will also benefit by addressing the unmet needs such as drugs for the PPI unresponsive population. This niche patient subgroup is difficult to treat and is currently underserved.

Reasons to Purchase

Understand unmet needs in the upper GI disorder market based on key opinion leader comment. Benchmark key late-stage pipel

Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence

press@researchandmarkets.com — Fri, 20 Jul 2007 10:23:37 GMT

Introduction

Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishments approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patients, but rather is shared among stakeholders.

Scope

Analysis of what is meant by adherence, how adherent behavior of measured and the factors that impact whether a patient follows treatment advice Examination of the factors individual, economic and societal factors that influence whether a patient will remain adherent Assessment of the healthcare trends that are impacting adherence to drugs worldwide In depth case study analysis of programs created by governments and industry in order to foster adherence in chronically ill patient populations

Highlights

Physicians who do not take the time to understand their patients can negatively impact adherence by failing to take into consideration factors that may make it difficult for patients to follow a medication regimen. This can lead to physicians prescribing treatments that are prohibitively complex or missing opportunities to provide support services. The ideal approach would involve collaboration between a variety of stakeholders, including physicians, patient groups, payers and the pharmaceutical industry. However, collaboration has proven to be complicated, not least of all because there is little or no consensus about how to define or measure adherence. Reaching customers through customized interactions will help to make them feel as though they are valued and understood by the company. Furthermore, as regards disease management programs in particular, the more accurately targeted the program the more likely it is to effect a behavioral change in the patient.

Reasons to Purchase

Learn how communication between patients, physicians and the pharmaceutical ind

Stakeholder Opinions: Primary Brain Cancer

press@researchandmarkets.com — Fri, 20 Jul 2007 10:23:37 GMT

Introduction

Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.

Scope

Incidence, diagnosis and treatment of primary brain cancer, including treatment regimens by stage and ongoing controversies Unmet needs, emerging trends and commercial incentives in primary brain cancer Examination of pipeline activity and potential future opportunities for drug developers Stakeholder opinions and interview transcripts based on qualitative interviews with six opinion leaders from the US and Europe

Highlights

The standard set by drugs that have been approved for primary brain cancer is low; therefore drugs only need to demonstrate relatively modest improvements in survival to be adopted by physicians. A substantial opportunity also exists for a second-line chemotherapy to enter the primary brain cancer market. Several molecular markers have been associated with glioma. It is possible that these markers could significantly affect treatment patterns, resulting in a stratified glioma market. Targeted therapies could be reserved solely for patients whose molecular profile indicates that they will benefit from such drugs. The potential of Phase III pipeline drugs is limited by factors such as low efficacy and complicated delivery methods. Of the drugs in the Phase II pipeline for glioma, targeted therapies show most potential. In particular, angiogenesis inhibitors have considerable commercial potential because they may reduce the co-morbidity edema.

Reasons to Purchase

Identify the limitations of current therapy available to primary brain cancer patients and the potential of future therapy Understand current epidemiological trends in primary brain cancer and ongoing

Stakeholder Opinions: Irritable Bowel Syndrome - Potentially profitable market is open for the taking

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:40 GMT

Introduction
Irritable bowel syndrome (IBS) is a common disease affecting 1020% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed.

Scope
Epidemiology and patient segmentation in irritable bowel syndrome (IBS), including a breakdown of the patient population by gender and symptom type
Discussion of issues with regards to IBS patient presentation, referral patterns and diagnosis such as the new Rome III diagnostic criteria
Overview of the current treatment controversies and unmet needs, including the market withdrawal of Novartis Zelnorm (tegaserod)
Analysis of clinical trial design in the R&D drug pipeline for new IBS drug therapies in 2007
Highlights
Despite the substantial impact IBS can have on sufferers well being, about 7080% of sufferers have not been formerly diagnosed. Although many patients will have seen a doctor or nurse for their symptoms, they remain undiagnosed and may have visited a healthcare professional on several occasions before being formally diagnosed with IBS.

Physicians frequently do not recognize IBS as a distinct disease. Continuing physician education is needed to change this attitude and improve diagnosis, particularly in the primary care setting. A simple and easily accessible diagnostic tool adapted specifically for non-specialists and clear peer reviewed treatment guidelines are needed.

The pipeline can be described as relatively innovative. The serotinergic class accounts for a third of candidates, however, the poor safety record and market withdrawal of Lotronex (alosetron) and Zelnorm has cast doubts over the potential of this class. FDA non-approval of cilansetron is another setback for the serotinergics.

Reasons to Purchase
Quantify the key target segments of the IBS patient population across the seven major markets
Gain i

Commercial Insight: Osteoporosis - Risk management and reformulation offer best defense against generic onslaught

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:34 GMT

Introduction
The osteoporosis market is due a major upheaval when market leader Fosamax (alendronate) loses its US patent. The resultant heightened competition will force market players to implement radical lifecycle management strategies to safeguard their franchise revenue. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.

Scope
This report focuses on the leading therapies used in osteoporosis, with sales and volume country- and indication-specific forecasts to 2016
Assessment of current and future opportunities and threats in the osteoporosis market across the seven major pharmaceutical markets
Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets
Lifecycle management case studies show how previously successful strategies should be applied in todays market
Highlights
Reformulations of marketed products have helped rejuvenate the calcitonin and bisphosphonate markets amid genericization. Arguably the most exciting is the Roches Boniva (ibandronate) reformulation which will generate substantial revenue as both an oral monthly and injectable quarterly product.

Following a number of recent reports that have concluded that vitamin D and calcium supplementation decreases the risk of cancer there is further support for the strategy to include a popular supplementary medication as either a combination pill or separately within the prescription brand packaging.

Eli Lilly has successfully launched two very different therapies to treat osteoporosis. Evista (raloxifene) and Forteo (teriparatide) The two products have been successful, being the third and fourth highest selling products on the osteoporosis market. In 2006, Evista generated sales of $739m and Forteo returned revenue of $574m.

Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the osteoporosis sales of k

Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:34 GMT

Introduction
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Tevas Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of a new MS treatment for six years.

Scope
This report focuses on the leading disease-modifying therapies used to treat MS, with seven major market (7MM) sales and volume forecasts to 2016
Assessment of current and future opportunities and threats in the MS market across the 7MMs
Future market events that are expected to affect drug revenues are discussed and quantified for each of the 7MMs
Lifecycle management case studies show how previously successful strategies should be applied in the current and future MS market
Highlights
Despite the comparatively large MS population, the UK only accounted for 1.1% of the 7MM total in 2006. Datamonitor believes the UK has potential to be a much more profitable and attractive MS market. If treatment rates were on par with Germany, the UK market could have been worth $293m in 2006almost six times higher than the actual value.

In order to successfully position a new drug class in the market, future market players must have a clear and focused marketing strategy. With Copaxonelaunched in 1997Teva has set the benchmark, and by utilizing similar tactics, future MS players can successfully position novel therapies in the market.

There remains a large opportunity for current and future players to cement and develop their positions in the MS market. To ensure continued revenue and to minimize franchise risk companies can follow Biogen Idecs strategy to market two or more products and show commitment to the MS community through long-term franchise investment.

Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the sales of key marketed brands
Quantify the future size of the MS market, in term

Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:34 GMT

Introduction
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and Japan, Ambiens leadership status is finally under threat and the market is undergoing some dramatic changes

Scope
This report focuses on the leading prescription therapies used in insomnia, with sales and volume country- and indication- specific forecasts to 2016
Assessment of current and future opportunities and threats in the insomnia market across the seven major pharmaceutical markets
Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets
Discussion of lifecycle management and branding strategies, focusing on Sanofi-Aventis, Sepracor and Takeda with insight from opinion leaders
Highlights
Sanofi-Aventiss continuing market leader status is attributable to astute portfolio management, beginning with the launch of a controlled release formulation of Ambien, Ambien CR, which Datamonitor forecasts to attain seven major market sales of $1.98 billion by 2016.

Strong branding supported by direct-to-consumer (DTC) advertising is an essential element to successful penetration of the insomnia market. Of the three insomnia products launched in 2005, Sepracors DTC advertising campaign for Lunesta has been the most successful owing to the pervasive use of a strong marketing symbol.

Although Takedas DTC advertising of Rozerem is distinctive, the strategy has been criticized by interviewed opinion leaders for being unnecessarily complex, a factor which hinders the target audiences understanding of the drugs indication.

Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the sales of key marketed insomnia products
Quantify the future size of the insomnia marke

Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:33 GMT

Introduction
Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical antipsychotics and the remaining branded antidepressants will see the depression market value drop to 2016.

Scope
This report focuses on the leading pharmacotherapies used to treat depression with sales and volume country- and indication-specific forecasts to 2016
Assessment of current and future opportunities and threats in the depression market across the seven major pharmaceutical markets
Future market events that are expected to affect drug revenues are discussed and quantified for each of the seven major markets
Lifecycle management case studies show how previously successful strategies should be applied in todays market
Highlights
Sales of atypical antipsychotics in depression are set to be stimulated by anticipated positive clinical trial data investigating the use of Seroquel (quetiapine) in this indication. Datamonitor forecasts peak class level seven major market sales of $1.43 billion in 2008, followed by a decline due to competition from pipeline drugs and generics.

Timing of launch of Wyeths reformulation Pristiq (desvenlafaxine) would appear to be optimal. However, no evidence exists to indicate that it is an improvement over the parent compound Effexor (venlafaxine). By focusing Pristiq on a niche cohort of depressed patients, Wyeth has done enough to diversify Pristiq to ensure moderate success.

The introduction of newer generation antidepressants such as the SNRIs Effexor and Cymbalta (duloxetine) and the SSRI Lexapro (escitalopram) into the Japanese depression market will drive its value considerably, resulting in a 52% increase by 2012.

Reasons to Purchase
Assess the impact of events such as patent expiries and new product launches on the depression-

Monoclonal Antibodies Report Market Model

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:33 GMT

Introduction
The model provides a comprehensive analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Analyze historical and forecast sales for all mAb products in the PharmaVitae universe
Assess all pipeline mAbs currently in development from pre-clinical testing to pre-registration

Monoclonal Antibodies Report Part I

press@researchandmarkets.com — Tue, 10 Jul 2007 08:36:33 GMT

Introduction
The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

Scope
Comprehensive financial strategic analysis of the mAb market out to 2012
Global sales forecasts to 2012 for all marketed and Phase III mAb products
Analysis of market trends by product, company, therapy area, technology and target type
Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics
Highlights
The overall ethical pharmaceutical market is expected to face a decline in sales over 2011 to 2012 as a result of the patent cliff. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.

Over the period 2006-12, the mAb market segment will achieve a sales CAGR of 14.2% versus a small molecule sales CAGR of 0.6%. The main barrier to sales growth for small molecules is exposure to material generic competition, which will have no effect on mAbs out to 2012.

mAbs currently command a two-fold average revenue per product premium over small molecules. Positive factors supporting this premium include a higher demand due to addressing therapy areas of high unmet need and lower competitive intensity due to accessing novel target space.

Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Understand the challenges and barriers to entry for new players seeking to venture into the mAb market
Understand the nature of the generic threat across different molecule types and the insulation of mAb products from biosimilars out to 2012

Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey

press@researchandmarkets.com — Tue, 19 Jun 2007 16:13:36 GMT

Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.

Scope of this title:

Review of the disease definition, classification and key patient segmentation for female sexual dysfunction Assessment of the current unmet needs in the treatment of female sexual dysfunction Exploration of the screening, presentation and referral patterns within the female sexual dysfunction population in the 5EU and US Prescription and treatment trends among important subcategories of female sexual dysfunction, such as hypoactive sexual desire disorder (HSDD)

Highlights of this title:

Testosterone therapies are already widely used among women with hypoactive sexual desire disorder and female sexual arousal disorder. There is a significant market for a formally approved testosterone product for women, with 85% of prescribers willing to switch existing testosterone users onto an approved product. There is a distinct need for more specialized services in support of those with sexual functioning problems. There is no clear referral pathway for primary care physicians and no specialist service for patients to present directly to. This causes a barrier to presentation, diagnosis and treatment. The identification and classification of FSD is biased by physicians perception. A woman presenting with sexual difficulties could receive a variety of diagnoses or even no diagnosis at all. There is a need not only for a more holistic approach to sexual dysfunction, but also for validated and consistent tools to assess and diagnose patients.

Reasons to order your copy:
Understand key opinion leaders views on topical issues in the female sexual dysfunction market

Translational Medicine: Bridging Pharmaceutical Discovery And Development With IT (Review Report)

press@researchandmarkets.com — Tue, 19 Jun 2007 16:13:35 GMT

This report consists of five sections: Market Focus, Technology Focus, Strategy Focus and two Databook sections, bringing together all of the documents that comprise our pharmaceutical technology research theme entitled "Translational Medicine: Bridging Discovery and Development with IT".

Scope of this title:

Translational Medicine - Drug Development Transformed? (Market Focus) Enabling Translational Medicine with Business Intelligence (Technology Focus) Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus) US and Europe IT Spending on Business Intelligence to 2012 (Databooks)

Highlights of this title:

Existing business models are called into question, driving translational medicine Translational research requires BI technology components BI vendors with high market readiness will realize the most success in the pharmaceutical industry

Reasons to order your copy:
Gain valuable industry insight into the market drivers and inhibitors for translational medicine Align your go-to-market strategy with both the organizational and technology needs of the pharmaceutical industry Quantify the current and projected market opportunity for business intelligence tools in North American and European Big Pharma and Biotech

Telehealth Spending In North America And Europe Through 2012 (Interactive Model)

press@researchandmarkets.com — Tue, 19 Jun 2007 16:13:34 GMT

As more healthcare providers and payers realize the benefits of telehealth, technology vendors will need to understand where opportunities exist in the telehealth market.

Scope of this title:

Highlights of this title:

Reasons to order your copy:
Understand the current and future direction of telehealth investment Compare opportunities across countries and market segments

Translational Medicine: Bridging Pharmaceutical Discovery And Development With IT (Executive Presentation)

press@researchandmarkets.com — Tue, 19 Jun 2007 16:13:32 GMT

Executive Presentations, delivered in a concise presentation format, enable our clients to access and share the content of our ongoing Pharmaceutical Technology Research Stream quickly and efficiently. This is an executive summary delivered in a presentation format based on the "Translational Medicine" theme.

Scope of this title:

Offers a high level view of the current market data landscape alongside challenges and solutions Provides some charts depicting forecast market data for business intelligence (BI) spending in the pharmaceutical market over the coming five years Identifies strategies vendors should use to develop more effective relationships and drive solution sales

Highlights of this title:

Market factors are driving adoption of translational medicine and specifically business intelligence (BI) solutions Vendors should align technology solutions to R&D workflow challenges Vendors with high market readiness in BI will realize the most success in the pharmaceutical industry

Reasons to order your copy:
Understand key drivers promoting the adoption of translational medicine Discover new ways to leverage relationships as a tool to drive market penetration Have an analyst present the slide pack, offering detailed knowledge on the trends occurring in the pharmaceutical industry

Worldwide Demand for Herbal and Non-Herbal Extracts, 2002-2012

press@researchandmarkets.com — Fri, 12 Jan 2007 16:40:20 GMT

This Database Table is a one-page table of hard-to-find numerical information. Database Tables are proprietary data sources covering specific information for the diagnostic, medical device, biotechnology, healthcare and IT sectors. Over 600 database tables are now available from Research and Markets.

A Note on Database Tables at Research and Markets: Please note that these database tables are very focused one or two page tables/charts. They are great as a quick snapshot of a given market, or to incorporate into your own presentations/forecasts. But they not give the detailed analysis and the comprehensive information found in the full industry/market reports. If you do require more detailed market research please visit the following categories at Research and Markets: Pharmaceuticals, Healthcare and Medical Devices, and Biotechnology.

European and United States Probiotics Market

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:14 GMT

Probiotics have been in existence for many years. However, it is only relatively recently that their wide-ranging potential health benefits have been properly appreciated, and that research has been undertaken to confirm their efficacy.

Within Europe, the dairy sector is the most developed segment of the market, with probiotic yoghurts and fermented milks, particularly in daily dose format, the most widely used. Consumer acceptance varies greatly across Europe, with Northern European and Scandinavian countries - those having a long traditional consumption of fermented dairy products - the most developed market. Probiotic dietary supplements have been slow to gain acceptance, but new applications are emerging all the time.

In the US, the situation is reversed, with dietary supplements by far the most accepted product format. It is generally established that US consumers are far more willing to take supplements than their European counterparts, thus explaining the large difference. Conversely, the US dairy probiotics market is very underdeveloped, as consumer-facing companies, such as Danone and Yakult, have invested less significantly in breaking the US market, compared with the considerable marketing spend observed in the US.

On the whole, probiotics represent a fast-growing market for functional foods manufacturers and suppliers, and producers must be sure that they do not squander their good potential by supporting a well thought-out strategy.

R&D Information Technology Markets for the U.S. Life Sciences Industry

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:14 GMT

Niche Participants to Gain Partnership Opportunities from Large Companies

Smaller participants are in danger of being nudged out by larger vendors with deep pockets and service capabilities to survive extreme price fluctuations. Intent on acquiring key top-tier customers, larger multiverticals are pushing combined service and product solutions, often at market floor rates achieved through local subcontracting. Smaller companies are being forced to prove their long-term financial viability to be considered in the running. Nevertheless, niche participants are likely to attract the large companies that wish to penetrate smaller pockets such as the discovery IT business. Such collaborations will help the big participants form long-term relationships with their buyers.

This research examines the R&D Information Technology Markets for the U.S. Life Sciences Industry. It offers revenue forecasts by market segments and covers key drivers and restraints affecting market growth. It also provides strategic recommendations to overcome market challenges. It analyzes the growth of demand from workflow specific systems to architecture technologies like grid computing and next generation databases.

Large Vendors Can Cross-Leverage Technology to Maximize Profits

IT in life sciences starts with end-user applications. Established end-user application providers have built an entrenched core competency in the life sciences vertical, which has acted to create a strong inside affiliation among research chemists and other strong influencers over time.

The real interest in 2003 is coming from relatively industry neutral IT segments such as data storage, computing, and grid technology. Vendors from these segments can cost-effectively leverage their products into the life sciences market by aggressively pursuing partnership channels with these established end-user applications vendors.

Changing Business Models to Dictate the IT Market

The phasing out of blockbuster drugs is being ex

World Contract Research Organizations Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:14 GMT

Various Incentives Needed to Attract Skilled Contract Personnel

Large and quickly growing contract research organizations (CROs) often find it difficult to align staffers' expertise closely with project requirements. This could be due to the unavailability of skilled scientists and the need to quickly staff projects. CROs have begun to utilize experienced contract personnel who are available on short notice and need not be immediately redeployed. The CROs, for their part, have to set up appropriate internal systems and permit the scientists to participate in programs reserved for full-time staff such as medical and retirement plans. Although contractors' pay rates are higher than those of full-time employees, the overall savings is higher.

This research examines the World Contract Research Organizations Markets. It offers revenue forecasts by market segment and covers key drivers and restraints affecting market growth. It also provides strategic recommendations to overcome market challenges. Revenue and shipment forecasts for World, U.S., European, and Asian markets are also provided.

Cost Pressures and Benefits Offered by CROs Promote R&D Outsourcing

Cost pressures are created in the pharmaceuticals market because of decreased client revenue due to patent expirations, price-fixing, and continually rising costs of R&D. Many companies are beginning to tackle the problem of mounting expenses by increasing sales resources to promote new products comprehensively, while simultaneously clipping overheads. However, despite several measures taken to contain costs, R&D expenditures continue to escalate, especially in biotech and specialty companies.

This increase in R&D costs is mainly due to high clinical testing expenses, which, in turn, is a result of the need for more comprehensive human testing of drugs that address complicated conditions, especially among children and seniors. CROs offer reduced testing costs to help companies in this initiative. They are able

U.S. In Silico Simulation of Biological Systems Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:14 GMT

Reducing Risk in Clinical Trials Prompts Acceptance of Simulation Technologies

With the potential to lower the risk and financial burden of clinical trials,

technologies that use computers to model and simulate biological systems are
revolutionizing the drug discovery field. Though clinical trials are in no
immediate danger of replacement by simulation technologies, pharmaceutical

companies are eagerly adopting new means of accelerating the drug discovery
and development process. As a result, the in silico simulation technologies
will quickly become essential tools in this industry.

This study analyzes the emerging markets for technologies that enable
researchers to model and simulate biological pathways, cells, tissue, and
diseases. It examines upcoming products, pricing strategies, and competitive
pressures. With such in-depth coverage, your company will be well prepared
to capitalize on a burgeoning industry.

Fear of Losing Exclusive Product Rights Pushes Drug Firms to Build In-House Systems

Considering the potential profits in selling a blockbuster drug, pharmaceutical

companies are understandably fearful of losing even a small portion of
revenues to partners in the drug discovery process, says the author of this
study. If a blockbuster drug is taken from discovery and development to
market by a pharmaceutical company working with a simulation company, a
bioinformatics company, and an information storage company, these outside
firms could claim a portion of the revenues.

In the bioinformatics market, it was possible for a pharmaceutical company to
circumvent this issue by bringing an analysis platform in-house. The in silico
simulation market is different, however, for the level of complexity inherent in
the systems makes the “buy or build” decision much more heavily weighted
towards “buy.” This is especially true for those few simulation companies that
have already validated their technology through case studies.

Competit

U.S. Cell Therapy Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:14 GMT

Expanded Applications in Stem Cell and Artificial Skin Products Reshape Demand

By using living human cells to produce engineered tissues and organs that
function like their natural counterparts, researchers in the field of cell therapy
are opening important new doors for tissue repair and regeneration. The skin
cell therapy market, for example, is poised for growth with emerging applications

for treating ulcers with artificial skin and for periodontal reconstruction
procedures. Meanwhile, in the stem cell field, recent research on cord blood
stem cells and embryonal stem cells should produce promising results.

This Frost & Sullivan marketing consulting report analyzes the major segments
of the U.S. cell therapy markets, including organ, cartilage, skin, neurodegenerative
disease, and stem cell therapy markets. With its in-depth discussions of

up-and-coming applications and their expected impact on the marketplace,
this report offers its users a privileged view of the future of the industry.

R&D Costs Threaten the Viability of Start-Up Firms

“The high costs of development and lengthy FDA approval process has many
small start-ups facing millions of dollars in losses for several years,” write the
industry experts responsible for this report. Small tissue engineering firms will

have to conduct clinical trials with no guarantee that their product will ever
be approved. Especially for companies working to produce one specialized
product, the costs of R&D could be a major obstacle to survival.

With public funds drying up, market participants will need to find new financial
backers. Small firms might benefit from alliances with pharmaceutical
companies looking to enter the market. This report, which examines potential
industry challenges and presents strategic recommendations, can help your
company overcome hurdles and ultimately overtake competitors.

Companies Must Concentrate on User Training

Although researchers and scientists have been working

U.S. High Throughput Screening Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

Combinational Chemistry Drives Demand for Sophisticated Screening Processes

Pharmaceutical and biotechnology companies are racing to identify and test
new chemical entities that may be turned into therapeutic drugs. Advances in

combinational chemistry are resulting in a large supply of chemical
compounds that need to be screened for their efficacy in fighting disease.
Consequently, demand will rise for high throughput screening (HTS)
technologies, which enable researchers to screen large numbers of
compounds quickly.

This Frost & Sullivan research investigates the potential markets for HTS
consumables (supplies and instrumentation) and services. It examines business
drivers and restraints, tracks key trends, and provides expert revenue
forecasts. With such an essential tool at its fingertips, your company will be
poised to capitalize on this important and fast-growing field.

Speed and Efficiency Define Successful HTS Solutions

Market participants are focusing research on creating assays that will speed
up the pace of HTS, says the analyst responsible for this study. Most analyses

used in HTS involve several additions and incubations at different times within
the procedure. Homogeneous assays could offer important advantages over
these processes. By mixing all the ingredients needed at once, homogeneous
assays accelerate and simplify the entire process.

Automated solutions will be in high demand. The implementation of robotics
could help ease the bottleneck of compounds waiting to be tested. Use of
ultra high throughput screening (UHTS) devices will help researchers test a
greater number of compounds per day. This study identifies areas for potential
growth, allowing your company to optimize its resources and ultimately
maximize revenues.

Innovation and Cost Reduction Should Remain Top Priorities

To remain competitive, companies performing HTS need to update their
technology and shift to more efficient and cost-saving instrumentation, says
the analyst

U.S. Electronic Clinical Trials Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

Drive for More Clinical Trials Boosts Market Growth

The call for accelerated clinical trial cycles and a push by the Food and Drug Administration (FDA) to use electronic data capture (EDC) for pharmaceutical, biotech, and medical device trials is fueling the expansion of e-recruitment and data capture markets. Because clinical trial sponsors are determined to streamline the process of recruiting subjects and capturing case report information, online technologies will play an important role in achieving that goal.

The FDA's movement toward electronic recruitment and data capture should raise awareness for these solutions and drive traffic to private trials. This Frost & Sullivan research covers the markets for online recruitment and clinical trial information services plus electronic data capture services and applications. By examining market drivers and restraints and presenting expert forecasts, this study gives its users an important guide to a growing industry.

Overcoming Investors' Concerns A Top Priority

If venture capital firms do not see a minimum projection of five-fold growth in the short term for e-recruiting, they are likely to withdraw from these
types of business propositions, says the study's author. Venture capital firms are expected to tighten their healthcare rosters and divest risky investments
in the near future.

This might be a good time for more fundamental approaches to growth, such as smaller early stage investments and higher marketing endorsements by
respected non-profit disease research organizations, says the analyst. This study, which identifies emerging challenges and offers strategic recommendations, can help your company anticipate and overcome obstacles
that may lay ahead.

In-House Recruitment Efforts Could Restrict Need for Outsourcing

Although pharmaceutical firms stand to gain from electronic clinical trial solutions, participants in these markets face their greatest challenges from the
pharmaceutical companies themse

U.S. Orthopedic Joint Implant Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

Technological Advances Sponsor Market Growth

Manufacturers of orthopedic joint implants are introducing new products that will minimize prosthetic wear, enhance biocompatibility, and simplify surgical
procedures. Modular joint systems will allow surgeons to choose from a range of components to better fit their patients' anatomies, while the implementation of computer-assisted surgery will result in less invasive procedures. These new products and technologies will drive industry growth by making joint replacement a more viable option for prospective patients.

This Frost and Sullivan study analyzes the markets for orthopedic joint implants, examining the segments for hip, knee and shoulder joint implants separately. It also provides a chapter on global markets for hip and knee implants. By tracking technological trends and assessing their impact in the marketplace, this research offers its users a privileged view of the future of
the field.

Stringent Food and Drug Administration (FDA) Approval Process Threatens Profitability

The high costs of product development and lengthy clinical testing processes impinge on manufacturers' profitability, says the analyst responsible for this
research. The FDA's rigorous requirements significantly delay the time to market for new products. Manufacturers must first notify the FDA of their intent to market a device in the U.S. and then demonstrate that it is as safe and effective as similar products already in the marketplace.

To provide valid scientific evidence of safety and effectiveness, human clinical trials are required. For many manufacturers, this extensive and costly approval process has proven to be a major challenge. This study identifies challenges that all market participants will face, helping your company anticipate and overcome any obstacles that may lie ahead.

Mergers And Acquisitions Key to Smaller Participants' Success

The orthopedic implant market is highly competitive, says the analyst. The dominan

U.S. Probiotics Market

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

Market Success Depends on Consumer Education
The benefits of eating foods with probiotics, or live microbial ingredients, have been known for a century, but demand for probiotic foods has risen precipitously in the last few decades as more consumers reach for natural, healthful products. Nevertheless, most consumers are unable to differentiateone probiotic product from another. Probiotic companies must increase
customer education while expanding their promotion of probiotics to awidening pool of potential buyers.

This Frost & Sullivan report examines the U.S. market for probiotics, includingspecific analyses of the yogurt and dietary supplements markets. In addition, a
comprehensive analysis of the market for probiotic cultures/bacteria is included in this research. By evaluating market drivers and restraints, tracking
emerging trends, and providing expert forecasts, this study offers companies a comprehensive guide to the future of the industry.
Innovative Products and Convenience Will Attract New Customers

Product innovation is a key factor for increasing market share, says the author of this study. The introduction of diverse products with new probiotic
strains has had a significant impact on the growth of the yogurt market in recent years. For most consumers, though, taste and convenience will continue to be the most important selling points.

Foods that are easy to eat, taste good, and are healthy are more realistic for the current American lifestyle and have better chances of success in this competitive market. This report examines consumer needs and offers strategic recommendations, helping market participants attract new customers and accelerate gains.

Manufacturers Strive to Overcome High Costs of Producing Quality Products

Incorporating high-quality strains into functional food systems or dietary supplements involves greater investment, indicates the author. However, consumers may not be willing to pay more for products whose b

U.S. Antiarthritis Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

Market Leaders Focus on Technology

Recent advances in drug discovery by biotechnology companies have jump-started
languishing antiarthritis markets. Biotechnology industry participants
long ago recognized the many untapped opportunities in the arthritis market.
Now, they are at the forefront with immune system discoveries works and

innovations for treatments and possibly prevention of rheumatoid arthritis
(RA).

This Frost & Sullivan research evaluates the current state of the U.S. prescription
arthritis market. It forecasts revenues, growth, and product pricing in
three major segments, and covers present and future therapies. Market drivers,
restraints, demand analysis and more empowers your success.

Marketing Innovations Key to Maximizing Return

Research shows that of an estimated 43 million people afflicted with arthritis
in the U.S., only about eight percent are receiving treatment. Successful manufacturers

of antiarthritic treatments must educate users and the healthcare

industry about new drug discoveries through aggressive marketing campaigns
to become market winners.

The growing percentage of the U.S. population suffering from arthritis can
make demand skyrocket for antiarthritic drugs, states the author of this
research.

New Opportunities with Accelerated Market Acceptance

Antiarthritic markets are expected to grow with the introduction of new
drugs and treatments. New disease-modifying anti-rheumatic drugs (DMARDs)
are the first of their kind in a generation.

Most of the DMARDs have been available in the market for decades, some
for 70 years, in the treatment of RA, states the author. This market got a
new life with the launch of products which gained immediate acceptance.
Arthritis is one of the most prevalent diseases in America. This Frost &
Sullivan research offers an in-depth analysis of the U.S. antiarthritis markets. It
highlights the treatments available for RA, the most debilitating form of arthritis,

and reports on new treatment

U.S. Telephony-Based Speech Technology Software Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

The future of speech technologies is finally brightening. Not only has the technology improved greatly with advancements in natural language understanding, accuracy and quality of voice, but also a number of end-user businesses are now in a position to take advantage of voice interface technologies. This report analyzes new trends and challenges in telephony-based speech technology software market and gives solid advice on how your company can take advantage of the opportunities emerging in this market. It offers in-depth insights into the various applications for speech technology software and web voice interface. It can help your company to overcome challenges, develop strategies and target each application to improve market penetration. From Frost & Sullivan.

U.S. Telephony Speech Recognition Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

Recent breakthroughs in telephony speech recognition products and services and their coverage in the media are prompting incredible strides in this formerly slow-growth industry. This Frost & Sullivan report presents a clear view of opportunities and changes in the market, including crucial discussions for gaining market share in speech technologies. It offers exclusive analyses of drivers and restraints of growth in major segments of the market, including automatic speech recognition software, speaker verification, text-to-speech software, and voice interface network services. Profiles of key industry participants are included.

Key Alliances and Partnerships in the World Drug Discovery Industry

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

This Frost & Sullivan research service titled Key Alliances and Partnerships in the World Drug Discovery Industry provides a description of the pharmaceutical business of the top ten pharmaceutical companies in the industry. It offers a comprehensive listing of products that are in development, as well as those in the market. This research service also analyses the key alliances of these established pharmaceutical companies.

Technologies

The following technologies are covered in this research:

- Clinical Development: Clinical trials, or human tests to determine the safety and efficacy of potential drug candidates are typically conducted in three sequential phases, although the phases may overlap. Successful clinical trials will result in the filing of a new drug application (NDA).
- Drug Discovery: Drug discovery includes structural biology, lead generation, lead optimization and process research and development.
- Genomics: Genomics refers to the biological discipline, which involves identifying the genetic basis for human disease.
- Hit: This refers to the library component whose activity, as measured in assay, exceeds a predefined, statistically relevant threshold.
- Lead Compound: A compound that exhibits pharmacological or biochemical properties that suggest its value as a starting point for drug development.
- Potency: The amount of a drug required to effectively treat the disease - the greater the potency, the smaller the required dose.
- Selectivity: The extent to which a drug interacts only with the target. Enhancing selectivity may lower the probability of harmful side effects.
- Structural Biology: Structural biology is the process of cloning, expressing and purifying protein targets to create information about their functions and how they interact with drug candidates.
- Toxicity: The presence and significance of any harmful side effects.

Market Overview

Strategic Alliances and Increasing Trend of Licensing Deals to Boost Productivity of Pharmaceuti

Strategic Analysis of U.S. Food Emulsifiers Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

This Frost & Sullivan research service titled U.S. Food Emulsifier Markets provides an overview of food emulsifiers along with their different applications such as in baked foods, confectionery, dairy products, margarine, and shortening. The study also provides forecasts, market drivers, restraints, and challenges faced by emulsifier manufacturers.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

- Foods

Technologies

The following technology is covered in this research:

- Membrane separation technology

Market Overview

Food Emulsifier Markets in the United States Witness High Degree of Consolidation
Due to the strong domination of global manufacturers, participants in the markets for food emulsifiers are increasingly focusing on establishing a global presence. This has proved tough for certain food emulsifier enterprises due to the pricing pressures exerted by established manufacturers. Of the 40 emulsifier units established across the world, 25 are located in the United States. However, with growing consolidation in the food ingredient industry, the number of participants in the U.S. emulsifier markets is declining. In this scenario, companies need to tackle issues such as shortage of non-genetically modified emulsifiers and competition from the trans fat market. To stay ahead of such competition, U.S. emulsifier manufacturers need to expand their product portfolio into diverse applications, while simultaneously developing novel products.
Encouragingly, food emulsifiers, owing to their functional potential, form an indispensable part of food products such as chilled dairy products, high-priced breads, as well as low-fat spreads that demand organoleptic superiority, stability, improvement in volume, and a longer shelf life. Further, the application of modern food processing techniques is driving the expansion of food production and new product development in diverse segments such as dairy, baker

Strategic Assessment of World Predictive Toxicology Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:13 GMT

This Frost & Sullivan research service entitled Strategic Assessment of World Predictive Toxicology Markets covers topics such as genomics, proteomics, metabolomics, QSAR, mechanistic approach, and non- mechanistic approach. In this research, Frost & Sullivan's expert analysts thoroughly examine the Mechanistic Predictive Toxicology and Non-mechanistic Predictive Toxicology markets.

Benefits of this Service

New Market Strategies to Address Major Predictive Toxicology Market Challenges
The predictive toxicology market has been faced with major challenges including, high costs, inaccuracy of predictions, and receiving FDA approval. This research targets specific predictive toxicology market challenges and suggests new strategies to overcome the barriers in the market.

Primary Research Identifies New Market and Technology Trends
The predictive toxicology market is evolving at a unprecedented rate in all market segments. This research uncovers novel market and technology trends, which are beneficial to manufacturers.

Detailed Revenue Forecast to Help Manufacturers Develop Future Plans
The predictive toxicology market is expected to change over the forecasting period from 2004-2010. Frost & Sullivan’s analyst expertise has strategically predicted the future market, which will enable manufacturers to develop future business strategies to stay competitive in the market place.

Detailed Company Profile
A company profile is provided presenting companies and their accomplishments. In addition, the analysis presents future prospects for this field.

Thorough SWOT Analysis
The Strengths, Weaknesses, Opportunities and Threats for the Predictive Toxicology markets are discussed in detail. This provides a great structure for manufacturers to prepare for the future market.

Market Sectors

- Mechanistic Predictive Toxicology

- Non-mechanistic Predictive Toxicology

Technologies

- Non-mechanistic approaches - Pattern recognition generated from the statistical analysis of

Current Clinical Applications and Trials of Stem Cell - Based Therapies

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Ethical Concerns Posing Challenges to the Development of Stem Cell Research
Despite their potential to address several unmet medical conditions such as neurodegenerative diseases and cancer, ethical social as well as legal issues are restraining the ongoing development of stem cell-based therapies. Stem cell research involving somatic cell nuclear transfer (SCNT) is one of the main causes for the worldwide debate, centered more on the source of the stem cells used for research purposes. As a result, companies are facing stiff opposition from political as well as religious groups for their embryonic cell-based technologies and many research institutes are adopting their policies with respect to the ethical use of the human embryonic tissues. Such policies are in turn affecting the overall research process for several companies that are working in collaboration with such institutes.
This Frost & Sullivan research service is an analysis of the current clinical applications and trials of stem cell-based therapies. It provides a comprehensive and comparative analysis of the worldwide research initiatives as well as regulatory frameworks in all major participant countries. Further, it also covers most of the major global companies involved in stem cell-based research and includes analysis of the potential stem cell based therapies market based on the forecast patient base for various diseases.
Increased Funding Providing a Boost for Stem Cell-based Research
In recognition of its overwhelming potential, there has been an increase in research funding across the world for stem cell research. Apart from venture capitalists taking interest in this area, government funding agencies are also increasingly recognising the medical treatment potential present in stem cell research. While researchers in the public sector are best positioned to develop stem cell-based therapies, several biotechnology and pharmaceutical companies are working in collaboration with academic ins

Proteomics: Promising Research, Potential Applications, And New Developments (Technical Insights)

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Proteomics research is growing at a rapid rate and has become one of the most important areas of investigation in biotechnology. There are proteomics
programs in nearly every major biotechnology and pharmaceutical firm, and critical developments are virtually impossible to track.

Technical Insights report separates the good news from the mundane by providing the following:

- A detailed overview of technological advances in development laboratories

- Identification of key companies and developers and provision of estimates of timelines for commercializing technology

- Definitions of key markets and applications

- Reporting on technology drivers as well as obstacles in the way of commercial success
- A detailed list of key contacts in the field, including names, titles, addresses, phone numbers, e-mail addresses, and URLs

Proteomics is not the study of proteins one by one, as has traditionally been done, but a highly automated endeavor operating on a massive scale.
High-throughput is the operative phrase, with increasingly sensitive assay techniques, the integration of multiple techniques into a single platform,
and robotics and computers taking the place of lab technicians. A great challenge lies ahead, therefore, for scientists to develop effective systems
with high-throughput, suitably sensitive arrays, and a complicated level of integration.

Proteins are the building blocks of tissues and cells, circulate in the blood to eliminate disease, regulate body temperature, digest food, synthesize
other proteins and small molecules, and in general perform all the work necessary to keep an organism working. Under- or overproduction of proteins
is implicated in many human diseases. Thus, knowing which genes are responsible for which proteins gives medical science a point of attack
for potentially curing many illnesses.

In the 1980s, when working with DNA and characterizing genes became easy, vast numbers of researchers in biology abandoned whatever they
were studyi

Competitive Technology Intelligence (Technical Insights)

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

This report from Technical Insights shows you how the best-in-class organizations can use competitive technology intelligence (CTI) to stay aware of what the other guys are up to...and how this knowledge translates into critical decisions that will help your company stay ahead of the pack. The report first looks at CTI as a growing business practice, and shows you how to get started. It pulls together a wealth of interviews, case histories, tips and pointers from top industry insiders, to give you the how-to's of CTI, including building your intelligence system...setting up communication networks, and putting together a crack CTI team.

Biotech Revolution, The (Technical Insights)

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Technical Insights brings you up-to-date on the biotech revolution sweeping medicine and industry. Packed with valuable technical and market data, the Report gives a comprehensive analysis and forecast of the biotechnology industry for 66 specific market sectors. Research at facilities at the forefront of R&D is discussed. Products under development, with applications ranging from softening blue jeans to producing life saving drugs, are examined. Throughout the emphasis is on market potential and barriers to commercialization to assist you in making informed strategic decisions. Covering the full spectrum for current medical and industrial biotech applications, this Report gives a clear picture of the market potential of biotechnology products.

European and United States Food Antioxidants Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Both the European and US antioxidants industry are highly diverse, supplying a range of different products to a number of different end-user markets. This report considers only the food and beverage applications. Overall, the US and European markets are experiencing revenue growth of just 3.4 percent, although this figure obscures the much higher growth rates of some products, including tocopherols and rosemary extracts. Growth is driven by a number of different factors, including increased consumption of snack foods and convenience products, and increased consumer concern about food safety issues.

The market includes both synthetic antioxidants, such as hindered phenols and gallates, and natural antioxidants, such as ascorbates, tocopherols and herb extracts. These natural products are becoming increasingly popular with consumers, but manufacturers are facing declining prices where Asian competitors have entered the market.

Rosemary antioxidant manufacturers in particular are deeply affected by what some have described as unclear and absurd legislation, which prevents the declaration of rosemary antioxidant extract as an antioxidant ingredient, or as a flavour.

Operator Strategies for Fixed-to-Mobile Convergence in Western Europe

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Fixed-mobile Convergence Gaining Momentum in the European Telecommunications Market
With the focus shifting from access technologies to applications and services, fixed-mobile convergence (FMC) is gaining momentum in the European telecommunications market. As such, changes are becoming apparent across the value chain-from the end user to the core network infrastructure-and telecommunication carriers and service providers will need effective strategies to exploit the opportunities provided by FMC. The penetration of the wireless local area network (WLAN) technology and its integration with broadband and cellular data, coupled with the development of voice over WLAN products and solutions, is expected to enhance the scope of FMC. The implementation of IP multimedia subsystem (IMS), which enables the use of a single application platform, is likely to help in reducing operational and capital expenses. This is expected to prompt carriers to develop new applications and services due to lower investment requirements. Such factors are anticipated to change the vertically structured, access technologies-based telecommunications market to a horizontal one that emphasises applications and services.
This Frost & Sullivan research service examines the European telecommunications market, segmenting it into fixed, mobile and integrated carriers. It also discusses the various market trends and opportunities while providing in-depth analysis of market share, forecasts, market drivers and restraints, fixed-mobile convergence operator strategies and revenues. Strategic recommendations offered in this study enable companies to align their positioning strategies to benefit from the changing market conditions and obtain maximum return on investment.
Clear-cut Strategies at Application, Service, Network and Device Levels to Combat Uncertainties in the Telecommunications Market
Increasing competition, both between and within the fixed and mobile industries, has spurred telecom service

Life Sciences Funding in Europe 2005 (Phase I) - Sources of Funding

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Investment in Fundamental Research is Crucial to Developing Commercially Feasible Medical Applications
In the face of ongoing advances in medical applications, a significant challenge facing European Union (EU) research policy is the need to build an improved scientific base through investments in life sciences and biotechnology. In order to identify appropriate therapeutic and diagnostic methods (theranostics), detailed investigations have to be carried out in an orderly way at both the cellular and organ system levels. While advanced medical applications such as comparative genomics and proteomics can provide lucrative financial returns, there is a need to ensure a conducive environment for refining these technologies. Hence, framework programmes (FPs) have to cater to both basic and applied research and companies need realize that fundamental research is the precursor to setting the groundwork for commercialising any application.
This Frost & Sullivan research service analyses the life sciences funding in Europe. The study lists the key trends in the funding of life sciences and has been segmented based on the perspectives from the European Commission and funding organizations in the United Kingdom, Germany and France.

Greater Emphasis on Translating Technologies into Meaningful Clinical Applications
While evolving technologies have been revolutionising the biological science domain, the European Commission, in tandem with other research councils, are focusing their attention on specialised research themes that have the potential to bring sound economic returns. Ongoing projects have been devised in such a way that the research and technological developments help in gaining sufficient knowledge on enhancing product development. Molecular disease-based approaches appear to have greater theranostics value and with their ability to compliment traditional medicine, the emphasis is strictly on converting such technologies into meaningful clinical applications.
F

Advantages and Disadvantages of Increasing Pharmaceutical R&D Outsourcing to India and China

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

International Pharmaceutical Companies Develop Research Base in India and China

Beleaguered by ever-increasing cost pressures, shorter product life cycles and various regulatory challenges in the West, the pharmaceutical industry is turning to opportunities in low-cost Asian countries such as India and China. Alliances with local companies, contractual outsourcing arrangements and establishment of local subsidiaries enable these enterprises to access openings in both countries, especially in the area of pharmaceutical research and development (R&D).

This service analyses the advantages and disadvantages of pharma R&D outsourcing to India and China. The study discusses the various trends and opportunities in each country while providing in-depth market share analysis, forecasts, drivers, restraints, and revenue forecasts. It also enables companies to align their positioning strategies to benefit from the changing environment and obtain maximum return on investment.

Advances in Microscopy--A Global Technology Assessment (Technical Insights)

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Advances in Microscopy Increase Success of Clinical Trials
Rapid technological advances in microscopy foster research on cellular processes and boost pharmaceutical development. These breakthroughs allow cost-effective ‘high-content screening’, which monitors live cells, thus reducing instances of clinical trial errors such as adsorption, distribution, metabolism, excretion, and toxicology profiles (ADMET). High-content screening, the latest in the high-end microscopy arsenal, increases chances of drugs satisfying increasingly stringent regulatory safety standards. Cytological profiling is also progressively utilized in trials involving drugs with highly specific biochemical effects, such as kinase inhibitors. Further, progress in imaging technologies and labeling techniques in the life sciences sector enables charting of prominent events within living cells in real-time and in three dimensions (3D).
This Technical Insights study identifies and analyzes not only global emergent, but also novel applications of existing microscopy technologies. The research service also offers in-depth information on R&D and product development. It looks at market trends, drivers and restraints in addition to technical challenges. Case studies, divided into categories by company and university, are included to aid participants plan for the long term effectively.

Microscopy Vital Part of Composition Studies and Non-destructive Testing
As technology in the materials and electronics sector becomes increasingly complex and cutting edge, microscopy is being deployed as an integral part of the multi-billion dollar industry of composition studies and nondestructive testing. Microscopy or visual inspection is, currently, the primary evaluation method of a growing number of quality-control programs to appraise the condition and quality of a weld or component.
The need for more sophisticated instrumentation will increase as companies develop advanced engineering, industrial, and

Strategic Analysis of the World Clinical Development Pipelines in the Pharmaceutical Industry

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

Productivity is Key for Continued Economic Development of the Pharmaceutical Industry

2004 was a successful but turbulent year for the pharmaceutical industry, with several key mergers and industry consolidations matched with high profile failures in the clinical development of new products. The pharmaceutical industry has been traditionally reliant on a small number of blockbuster drugs that generate annual revenues in excess of $1 billion. However, the market is moving away from this trend and in 2005 the industry is expected to see the expiry of several major blockbuster patents and a drive towards pipeline diversification to compensate for a flood of generic products into the market. Pharmaceutical companies are likely to focus their attention towards computer modeling, data processing solutions and molecular biomarker discovery programs in a bid to improve overall productivity and reduce late stage drug attrition rates during the clinical trial phase.

This Frost & Sullivan strategic analysis offers a comprehensive overview of the clinical development pipelines in the pharmaceuticals industry. The research service highlights trends and clinical pipelines of the top ten global pharmaceutical companies. In addition to providing information on market drivers, challenges, and restraints, the study also analyzes and offers strategies to reduce clinical development costs.

Highly Specific Treatments a Key Solution to Combat Decline of Blockbuster Drugs

The pharmaceutical industry is gradually shifting towards the development of personalized and evidence based treatments due to continuous improvements in diagnostics. Indicators of this trend are the consolidation of the pharmaceutical and biotechnology industries, and investment in new biopharmaceutical products. An aging population that requires sophisticated treatments for complex areas of unmet medical needs also drives this trend. Here a single treatment for a wide range of disease indications is not an effec

End-User Analysis of the European Probiotics Market

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:12 GMT

This report provides End-User Analysis of the European Probiotics Market.

Effects of HIPAA in U.S. Healthcare Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:11 GMT

HIPAA-related Spending to Increase - Mainly in Managed Care Sector

As the 2003 deadlines for compliance approach, the impact of the Healthcare Insurance Portability and Accountability Act (HIPAA) is expected to create large spending within the healthcare industry, mostly focused on confidentiality training. The bulk of the technology spending is likely to occur in the managed care sector where fewer organizations are HIPAA compliant.

This Frost & Sullivan research analyzes the effects of HIPAA in U.S. healthcare markets. It provides valuable analyses of HIPAA-related spending and factors governing it and also identifies the areas of growth. The study covers applicability issues by technology and adoption patterns by hospital, physician practice, and managed care sectors.

ROI-based Spending on EDI to Dominate Commercial Market For HIPAA

The market for commercial electronic management report (EMR) and electronic data integration (EDI) products will substantially increase as a result of HIPAA. EMR for audit trail and access authorization purposes, and EDI for the conversion of transaction code set standards used in reimbursement, reports the author of this study. These products present the highest immediate need value to the industry in terms of standardizing both patient records access and reimbursement formats, which is vital to HIPAA compliance and financial revenue flow.

The resulting increase in storage needs of hospitals should make server-lease programs a highly attractive and cost-effective option for hospitals.

The HIPAA does not set any special software requirement standards for minimum compliance and conventional electronic proof of identity using user authentication fields, unique patient identifier generators, and code-set conversion menus are acceptable. The bulk of HIPAA-mandated refinements to clinical systems are thus likely to be incorporated into next-generation releases of commercial software.

HIPAA Budget Allocations Subdued by Other Fina

Strategic Analysis of Royalty Stacking for Pharmaceutical and Biopharmaceutical Products in Europe

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:11 GMT

Patent Concerns Restrain Growth in Pharmaceutical and Biopharmaceutical Sectors

Intellectual property rights dilemmas such as patent thickets and royalty stacking are proving to be obstacles for pharmaceutical and biopharmaceutical companies. The cost of obtaining multiple licences or making royalty payments for the use of research tools is significantly raising product development costs, constraining further research and slowing down investments. High product development and marketing costs imply that end users will be charged higher prices to recoup the expenses for obtaining patent licences.

This strategic analysis offers an in-depth study of royalty stacking for pharmaceutical and biopharmaceutical products. It offers a comprehensive overview of the patent and royalty stacking environments along with solutions to these issues and strategic recommendations on managing royalties. Key challenges, issues and drivers are provided to aid participants to effectively identify and capitalise on opportunities for growth.

Royalty Stacking Issues Shaping Drug Development and Strategic Alliances

Besides the patenting of common scientific knowledge, royalty stacking could also obstruct the acquisition of multiple patents held by diverse parties. This restriction on availability of introductory upstream breakthroughs is affecting further innovation and constricting research. It is also leading to crucial projects being put on hold or even abandoned mid way, affecting biotechnology sustainability and drug development.

Moreover, the pharmaceuticals industry is becoming increasingly reluctant to form alliances with biotechnology companies for fear of potential royalty stacking risks, which can reduce profits to a point where pursuing commercialisation is no longer viable, observes the analyst of this research. These issues are impinging on the ability of firms to commercialise new products and services with a reasonable degree of freedom and certainty about the risks of e

U.S. PLM Markets for Life Sciences

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:11 GMT

Competition in the PLM Industry Forces Average Contract Price Markdowns of Almost 50 Percent

Product lifecycle management (PLM) contract pricing takes a major hit due to a hyper-competitive account development strategy aimed at the life sciences industry. While some argue in favor of named user licenses, others debate its appeal to price conscious customers and instead prefer concurrent user license pricing. Although concurrent user pricing allows customers to increase the utilization of the PLM application at a bargain price, the industry is likely to prefer the named user pricing model post-2005. Either way, the industry is being forced to mark down total retail contract values at or slightly above cost levels- most often at 50 percent or lower.

This Frost & Sullivan research evaluates the key drivers and challenges in the PLM markets for life sciences. The study also analyzes the buying behavior of customers to help participants position their solution sets in the appropriate manner. It provides strategies to overcome the obstacles to success and assist participants in designing high-impact action plans.

Late Stage Adoption is a Promising Growth Avenue for PLM

There is a move to position PLM as the backdoor extension to enterprise resource planning (ERP) - especially among highly desirable sectors such as pharmaceuticals. Since 45 percent of life sciences companies have current or legacy ERP systems, license conversion to PLM is the natural next step. Once PLM gathers pace in the life sciences market, there are possibilities of fusing it with ERP systems to form a unified solution. This unified ERP-PLM infrastructure bypasses many of the complicated and expensive integration strategies, notes the analyst. However, such a change is likely to occur gradually within the next five years.

Product Document Management Driving Enterprise PLM Adoption

Industry consensus shows that product document management (PDM) is becoming the most prioritized utility with

U.S. Physician Practice Management Systems Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:11 GMT

‘Single Product’ Solution Offering Value for Money is the Need of the Hour

Vendors participating in the U.S. physician practice management systems (PPMS) market are facing the daunting task of offering an affordable ‘single product’ solution that caters to the extensive requirements of physicians. Care providers are more likely to be convinced if vendors provide a solution that can control their escalating overhead expenses and enable proper implementation, leading to optimum staff utilization and increase in revenue. To meet such high user expectations, vendors have to develop a cost-effective solution capable of performing a wide range of functions - for instance, quantification of procedures, tracking front office events, revenue flow analysis, evaluation of relative value and unit-wise productivity, and calculation of staff compensation and bonuses. In a nutshell, the focus should be on providing an affordable tool that can address workflow management by incorporating time-based productivity analysis/display coupled with templates mentioning details of patient management.

This recent research examines the drivers, restraints, and challenges influencing the PPMS markets covering integrated PPMS solutions, clinical care solutions, and billing and claims solutions in the United States. The study also evaluates the regulatory impact in the context of technological advancements besides providing revenue forecasts, competitive analysis, and strategic recommendations that help companies in devising suitable market penetration strategies.

Solo and Small Group Practices Provide Multiple Growth Opportunities

Nearly 53 percent of the total active private practitioners in the United States practise in small groups comprising three or less physicians. These groups are likely to proliferate further in the coming years, providing more market opportunities for application service providers and vendors offering integrated PPMS to this segment. Initi

U.S. Safety Devices and Containers Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:11 GMT

New Precautionary Legislation Concerning Safety Devices Drives Research and Development

The Occupational Safety and Health Administration's (OSHA) new directive states that healthcare providers select safety devices based on appropriateness of the procedure, effectiveness, cost, and availability. This is spurring research efforts to develop new devices, such as a low-cost, retracting needle syringe. The annual review of medical devices has made it mandatory for healthcare providers to document information about new or prospective safety device options as part of their exposure control plan. The recorded safety device must be used when it becomes available. More states are beginning to comply with these rules, increasing demand for improved products.

This new research service from Frost & Sullivan analyzes the U.S. safety devices and containers markets and provides an analysis of drivers and restraints that affect sales. It provides strategic analysis and forecasts, and industry trends along with potential market impact.

High Incidence in Needlestick Injuries Creates a Need for Safety Devices

For every 100,000 conventional needles used, 1 to 40 needlestick injuries occur. Approximately 2.7 percent of the needlestick injuries each year result in HIV exposure. Although the risk of being infected through a needlestick injury is low, the consequences are tremendous, says the analyst of this research service. Besides contracting bloodborne pathogen infections, other serious consequences include the psychological trauma of waiting for the serological results, side effects of prophylactic drugs, chronic disabilities, and denial of worker compensation claims. Personal changes such as sexual practices and delayed childbearing because of being infected increase the trauma associated with contracting these diseases.

Hollow-bore needles with noticeable traces of fresh blood present the greatest threat. This led to the adoption of needleless IV systems in the early 1990s,

U.S. Radiopharmaceuticals Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:10 GMT

Novel Radioisotopes Revitalize Marketplace

The introduction of new, novel radioisotopes and their combination with

innovative carrier molecules will bolster markets for radiopharmaceuticals—

the substances used in nuclear medicine imaging to detect functional or
metabolic disturbances prior to structural change. Commercial development
of alpha-emitters, for example, will provide radiologists with better tools to
target tumor cells and offer new opportunities for pharmaceutical firms.

This research analyzes the U.S. markets for radiopharmaceuticals, including
products for diagnostics and therapeutics, plus FDG (2-fluoro-2deoxy-D-glucose)
molecules, which are used in cancer applications. The study devotes a
section to radiopharmacies, examining market trends by region and by
application segment. By pinpointing market drivers and restraints and
providing expert revenue forecasts, this research gives its users a detailed
overview of the field.

Expansion of PET Installed Base and Distribution Networks Spur FDG Growth

FDG continues to be one of the fastest growing segments of the diagnostic
radiopharmaceuticals markets, demonstrating dynamic growth in 2001, says
the author of this study. FDG is expected to outperform competing oncology

diagnostics and will represent a significant portion of the total
radiopharmaceuticals markets by 2008. The expansion of positron emission
tomography (PET) scanners will bolster this growth, since FDG accounts for
more than 90 percent of imaging agents used with PET.

Meanwhile, improved distribution of FDG will help move agents to
radiologists more quickly. Because FDG has a short half-life, distribution must
be efficient and remain within a limited geographic region. Thus the

multiplication of facilities by key distributors will help boost revenues for this
type of agent. This study, which tracks emerging trends and assesses their
impact on each market, can assist your firm in developing the most effective
business pla

The European Contrast Media and Radiopharmaceuticals Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:10 GMT

Saturation in Some Segments While Growth in Others
There are significant changes taking place in the European contrast media and radiopharmaceuticals market as some segments experience growth while others lag. For instance, in the contrast media market, the introduction of new technologies that require less contrast agents - such as helical and spiral computed tomography (CT) - is limiting the growth of the X-ray/CT segment. On the other hand, magnetic resonance imaging (MRI) and ultrasound segments show great scope for expansion and are already experiencing considerable growth due to their wider application and superior contrasting features. The MRI segment is likely to show double-digit growth. A similar situation prevails in the radiopharmaceuticals market, with positron emission tomography (PET) agents experiencing greater demand than others.

This Frost & Sullivan research on the European contrast media and radiopharmaceuticals market offers valuable insights into the market dynamics and identifies the saturated segments along with those showing high potential for growth. This is likely to aid participants in devising suitable strategies to target the growing areas. The study also critically analyses the emerging class of products, the companies introducing these products, their stages of development and their potential impact in shaping the market and its revenues.

Optimisation of Opportunities in the Growing Segments Holds the Key to Expansion

Increased demand for MRI contrasting agents is primarily driving the contrast media market while the upsurge in demand for PET agents is boosting the growth of the radiopharmaceuticals market. MRI contrasting agents and PET radiopharmaceuticals are showing tremendous growth potential and are helping to balance the effects of market saturation and price erosion in the overall contrast media and radiopharmaceuticals market, remarks the analyst of this research. Companies that overcome the pricing threats and intr

World Medical Image Management Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:10 GMT

The big story in the medical image management field is the growing reliance of healthcare providers on picture archiving and communications systems (PACS). According to this Frost & Sullivan report, the question facing buyers today is not whether to implement PACS but when and how to do it and still remain competitive. The report answers these questions by offering a variety of cost-effective solutions, including mini-PACS, and analyzing the competitive strategies of the industry s most successful companies. Sales data and forecasts by region are also provided, as are 50 profiles of manufacturers, including Agfa, Ramsoft, Vidar Systems, and GE Medical.

World Diagnostic Imaging Equipment Markets

press@researchandmarkets.com — Tue, 09 Jan 2007 11:35:10 GMT

Because age related diseases are increasing, diagnostic imaging modalities are encountering solid market growth. This report uncovers and analyzes key market trends and growth opportunities in five industry modalities, giving its users information necessary to acquire hotly contested market share. With in-depth forecasting based on revenue growth, product pricing, and unit sales, this report provides a comprehensive industry view. Profiles of key industry participants are also included. From Frost & Sullivan.